Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
ACS Chem Neurosci
2012 Oct 17;310:767-81. doi: 10.1021/cn3000718.
Show Gene links
Show Anatomy links
Nonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake.
Ruggiero AM
,
Wright J
,
Ferguson SM
,
Lewis M
,
Emerson KS
,
Iwamoto H
,
Ivy MT
,
Holmstrand EC
,
Ennis EA
,
Weaver CD
,
Blakely RD
.
???displayArticle.abstract???
Current therapies to enhance CNS cholinergic function rely primarily on extracellular acetylcholinesterase (AChE) inhibition, a pharmacotherapeutic strategy that produces dose-limiting side effects. The Na(+)-dependent, high-affinity choline transporter (CHT) is an unexplored target for cholinergic medication development. Although functional at the plasma membrane, CHT at steady-state is localized to synaptic vesicles such that vesicular fusion can support a biosynthetic response to neuronal excitation. To identify allosteric potentiators of CHT activity, we mapped endocytic sequences in the C-terminus of human CHT, identifying transporter mutants that exhibit significantly increased transport function. A stable HEK-293 cell line was generated from one of these mutants (CHT LV-AA) and used to establish a high-throughput screen (HTS) compatible assay based on the electrogenic nature of the transporter. We established that the addition of choline to these cells, at concentrations appropriate for high-affinity choline transport at presynaptic terminals, generates a hemicholinium-3 (HC-3)-sensitive, membrane depolarization that can be used for the screening of CHT inhibitors and activators. Using this assay, we discovered that staurosporine increased CHT LV-AA choline uptake activity, an effect mediated by a decrease in choline K(M) with no change in V(max). As staurosporine did not change surface levels of CHT, nor inhibit HC-3 binding, we propose that its action is directly or indirectly allosteric in nature. Surprisingly, staurosporine reduced choline-induced membrane depolarization, suggesting that increased substrate coupling to ion gradients, arising at the expense of nonstoichiometric ion flow, accompanies a shift of CHT to a higher-affinity state. Our findings provide a new approach for the identification of CHT modulators that is compatible with high-throughput screening approaches and presents a novel model by which small molecules can enhance substrate flux through enhanced gradient coupling.
Apparsundaram,
Molecular cloning and characterization of a murine hemicholinium-3-sensitive choline transporter.
2001, Pubmed
Apparsundaram,
Molecular cloning and characterization of a murine hemicholinium-3-sensitive choline transporter.
2001,
Pubmed
Apparsundaram,
Molecular cloning of a human, hemicholinium-3-sensitive choline transporter.
2000,
Pubmed
,
Xenbase
Atweh,
Utilization of sodium-dependent high affinity choline uptake in vitro as a measure of the activity of cholinergic neurons in vivo.
1975,
Pubmed
Blumstein,
The neuronal form of adaptor protein-3 is required for synaptic vesicle formation from endosomes.
2001,
Pubmed
Bridges,
The antipsychotic potential of muscarinic allosteric modulation.
2010,
Pubmed
Chatterjee,
Characteristics of [3H]hemicholinium-3 binding to rat striatal membranes: evidence for negative cooperative site-site interactions.
1987,
Pubmed
Cheng,
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
1973,
Pubmed
Conn,
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
2009,
Pubmed
Ehrlich,
Endocytosis by random initiation and stabilization of clathrin-coated pits.
2004,
Pubmed
English,
Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter.
2010,
Pubmed
Evans,
Endocytosis and vesicle trafficking.
2002,
Pubmed
Ferguson,
Vesicular localization and activity-dependent trafficking of presynaptic choline transporters.
2003,
Pubmed
Ferguson,
Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice.
2004,
Pubmed
Ferguson,
The choline transporter resurfaces: new roles for synaptic vesicles?
2004,
Pubmed
Ferguson,
Dynamin, a membrane-remodelling GTPase.
2012,
Pubmed
Freeman,
Peripheral toxicity of hemicholinium-3 in mice.
1982,
Pubmed
Gates,
Regulation of choline transporter surface expression and phosphorylation by protein kinase C and protein phosphatase 1/2A.
2004,
Pubmed
Gilhus,
Myasthenia gravis: a review of available treatment approaches.
2011,
Pubmed
Greengard,
Synaptic vesicle phosphoproteins and regulation of synaptic function.
1993,
Pubmed
Guyenet,
Inhibition by hemicholinium-3 of (14C)acetylcholine synthesis and (3H)choline high-affinity uptake in rat striatal synaptosomes.
1973,
Pubmed
Holmstrand,
Ultrastructural localization of high-affinity choline transporter in the rat anteroventral thalamus and ventral tegmental area: differences in axon morphology and transporter distribution.
2010,
Pubmed
Holton,
Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization.
2005,
Pubmed
Hvalby,
Synapsin-dependent vesicle recruitment modulated by forskolin, phorbol ester and ca in mouse excitatory hippocampal synapses.
2010,
Pubmed
Iwamoto,
Na+, Cl-, and pH dependence of the human choline transporter (hCHT) in Xenopus oocytes: the proton inactivation hypothesis of hCHT in synaptic vesicles.
2006,
Pubmed
,
Xenbase
Knipper,
Regulation of hemicholinium binding sites in isolated nerve terminals.
1992,
Pubmed
Krantz,
A phosphorylation site regulates sorting of the vesicular acetylcholine transporter to dense core vesicles.
2000,
Pubmed
Kuhar,
Sodium-dependent, high affinity choline uptake.
1978,
Pubmed
Kása,
The cholinergic systems in brain and spinal cord.
1986,
Pubmed
Leenders,
Modulation of neurotransmitter release by the second messenger-activated protein kinases: implications for presynaptic plasticity.
2005,
Pubmed
Leonard,
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.
,
Pubmed
Letourneur,
A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains.
1992,
Pubmed
Levy,
Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.
1999,
Pubmed
Li,
Sorting of vesicular monoamine transporter 2 to the regulated secretory pathway confers the somatodendritic exocytosis of monoamines.
2005,
Pubmed
Linding,
Protein disorder prediction: implications for structural proteomics.
2003,
Pubmed
Lowenstein,
Rapid regulation of [3H]hemicholinium-3 binding sites in the rat brain.
1986,
Pubmed
Martorana,
Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?
2010,
Pubmed
Misawa,
Aberrant trafficking of the high-affinity choline transporter in AP-3-deficient mice.
2008,
Pubmed
Mulder,
Release of acetylcholine from hippocampal slices by potassium depolarization: dependence on high affinity choline uptake.
1974,
Pubmed
Müller,
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT).
2005,
Pubmed
Nakata,
Ultrastructural localization of high-affinity choline transporter in the rat neuromuscular junction: enrichment on synaptic vesicles.
2004,
Pubmed
Neumann,
Heart rate variability is associated with polymorphic variation in the choline transporter gene.
2005,
Pubmed
Okuda,
Substrate-induced internalization of the high-affinity choline transporter.
2011,
Pubmed
Parihar,
Alzheimer's disease pathogenesis and therapeutic interventions.
2004,
Pubmed
Rao,
Epitope-tagged dopamine transporter knock-in mice reveal rapid endocytic trafficking and filopodia targeting of the transporter in dopaminergic axons.
2012,
Pubmed
Rowe,
Attention-deficit/hyperactivity disorder: neurophysiology, information processing, arousal and drug development.
2006,
Pubmed
Ruggiero,
The endoplasmic reticulum exit of glutamate transporter is regulated by the inducible mammalian Yip6b/GTRAP3-18 protein.
2008,
Pubmed
Russell,
Cholinergic system in behavior: the search for mechanisms of action.
1982,
Pubmed
Sabbagh,
Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?
2006,
Pubmed
Sakrikar,
Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation.
2012,
Pubmed
Salazar,
Vglut1 and ZnT3 co-targeting mechanisms regulate vesicular zinc stores in PC12 cells.
2005,
Pubmed
Salazar,
The zinc transporter ZnT3 interacts with AP-3 and it is preferentially targeted to a distinct synaptic vesicle subpopulation.
2004,
Pubmed
Sandberg,
Characterization of [3H]hemicholinium-3 binding associated with neuronal choline uptake sites in rat brain membranes.
1985,
Pubmed
Sarter,
Choline transporters, cholinergic transmission and cognition.
2005,
Pubmed
Schmidt,
Congenital myasthenic syndrome due to a novel missense mutation in the gene encoding choline acetyltransferase.
2003,
Pubmed
Schmidt,
Biogenesis of synaptic-like microvesicles in perforated PC12 cells.
1998,
Pubmed
Simon,
Sodium-dependent high affinity choline uptake: a regulatory step in the synthesis of acetylcholine.
1976,
Pubmed
Simon,
Impulse-flow regulation of high affinity choline uptake in brain cholinergic nerve terminals.
1975,
Pubmed
Soreq,
Acetylcholinesterase--new roles for an old actor.
2001,
Pubmed
Suhre,
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2.
2005,
Pubmed
Sweet,
Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.
2001,
Pubmed
,
Xenbase
Tan,
A leucine-based motif mediates the endocytosis of vesicular monoamine and acetylcholine transporters.
1998,
Pubmed
Vogelsberg,
Cyclic AMP-mediated enhancement of high-affinity choline transport and acetylcholine synthesis in brain.
1997,
Pubmed
Voglmaier,
Distinct endocytic pathways control the rate and extent of synaptic vesicle protein recycling.
2006,
Pubmed
Wilens,
Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.
2007,
Pubmed
Wilkinson,
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
2004,
Pubmed
Yamamura,
Choline: high-affinity uptake by rat brain synaptosomes.
1972,
Pubmed
Zhang,
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.
1999,
Pubmed
van der Bliek,
Mutations in human dynamin block an intermediate stage in coated vesicle formation.
1993,
Pubmed
